Teva Pharmaceuticals (NYSE: TEVA) beat Q2 earnings estimates, but fell short of Street’s revenue targets. The drug manufacturer reported adjusted EPS of $0.53 on revenue of $3.87 billion for the second quarter of 2020. Teva also confirmed its full-year 2020 outlook. TEVA stock was trading up about 3% in the pre-market trading hours.
For fiscal 2020, the company reaffirmed its previously announced outlook. Revenues are expected to be between $16.6 billion and $17 billion and EPS is forecast to be between $2.30 and $2.55 for FY20.
Revenues slipped 7% year-over-year due to lower revenues from generics, OTC and COPAXONE in all regions and lower revenues from QVAR and BENDEKA/TREANDA in North America segment. Also, demand reduced for certain Teva products, resulting from the impact the COVID-19 pandemic had on purchasing patterns.
“During the quarter, we experienced lower sales of our generic and OTC products in all regions. The lower generics and OTC sales in Europe and International Markets were in line with our expectations, after the unusually high demand seen in the prior quarter due to the initial response to the pandemic,” said CEO Kare Schultz.
Aurora Cannabis, Inc. (NYSE: ACB) reported a wider loss for the fourth quarter of 2020, hurt by a 5% decrease in revenues. The company’s stock fell sharply during Tuesday’s after-hours
Stitch Fix (NASDAQ: SFIX) reported fourth-quarter 2020 financial results after the closing bell on Tuesday. The company reported an 11% increase in Q4 revenues to $443.4 million, beating Wall Street
Nike Inc.'s (NYSE: NKE) profit and revenue in the first quarter of fiscal 2021 surpassed the market's estimates and sent the NKE stock up by about 7% in the extended